Agoracom Blog Home

Posts Tagged ‘PPE’

Primo Nutraceuticals Inc. $PRMO.ca signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 8:07 AM on Wednesday, October 21st, 2020
  • Signed of a Memorandum of Understanding with Neo-Nostics(Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).
  • Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020
  • Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.

VANCOUVER, British Columbia, Oct. 21, 2020 – PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) announces the signing of a Memorandum of Understanding (MOU) with Neo-Nostics(Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China (“Neo-Nostics”) as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).

The Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020. Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.

The Neo-Nostics2019-nCoV IgG/IgM Rapid Testing Kit is currently registered with the FDA. Primo will be submitting the application for approval to Health Canada immediately. Neo-Nostics ™ has committed to supporting Primo’s efforts to obtain and maintain all necessary certifications and approvals for the sale and marketing of the Test Kits in Canada by granting access to all necessary documentation and clinical studies concerning the Test Kits.

Follow the link for a video demonstration: http://www.neo-nostics.com/skin/images/mp40.mp4

About the Neo-NosticsRapid Test Kits

The Neo-Nostics 2019-nCoV Antibody Detection Reagent Kit (Colloidal Gold Method) has the advantage of rapidity, convenience, high accuracy, and can make up for the shortcomings of professional requirements, time consumption and low positive detection rate of PCR nucleic acid detection, and can be used as an important supplementary detection method for the diagnosis of coronal pneumonia.

Through detection and calculation, it is found that the comprehensive accuracy rate of the Neo-Nostics2019-nCoV IgM Detection Reagent is higher than 95%.

During the worst period of the epidemic in China, the reagent kit was donated to hospitals and the CDC in the most severely infected areas of Hubei for clinical auxiliary diagnosis. At present, the verification reports made by three clinical units prove that the positive detection rate of clinically confirmed cases has reached 92%, which has exceeded the general detection effect. Not only negative or positive results can be detected, but also the early, middle and or recovery period of virus infection can be distinguished by the positive strength of IgM or IgG.
Source: Clinical study report conducted by the Institute of Virology, in the capital city of Hubei, China and The Chinese Academy of Sciences in Beijing, China.

DISCLAIMER: “The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time”.

Clinical Applications of Reagents

This reagent has been used by professionals in China since February 2020 in an area that was the hardest hit and impacted most severely by COVID-19, in the form of clinical auxiliary diagnosis.

The reagent kit was clinically verified by several professionals, hospitals, and universities respectively, and corresponding reports were used as reference.

At present, Iran, Italy, the United States, and other red zones have already adopted it . Neo- N osticshas CE declaration of conformity, local records of European Authorized Representative and FDA records in the United States.

View the FDA records here: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=669386&lpcd=QKO

Advantages of the Colloidal Gold Method

1. Quick – 10 minute results.

2. Simple – The detection results can be determined by the naked eye.

3. Sampling – Only fingertip blood or venous blood is required for detection.

4. It is suitable for clinical auxiliary diagnosis.

About the COVID-19 Detection Kit Market

According to a new report by Grand View Research, Inc., The global COVID-19 detection kits market size is projected to reach USD 4.63 billion by 2027 . The COVID-19 pandemic has posed several challenges to the global healthcare systems. As a result, companies are ramping up their production process to meet the demand or kits and reagents as well as at-home tests, thereby driving the market revenue. https://www.grandviewresearch.com/industry-analysis/covid-19-detection-kits-market?utm_source=prnewswire&utm_medium=referral&utm_campaign=hc_15-sep-20&utm_term=covid-19-detection-kits-market&utm_content=rd

Mr. Joey Zhou, CEO of Neo-Nostics(Suzhou) Bio-Engineering Co. Ltd. Comments:

“Penetrating the Canadian market with our advanced and highly effective test kit will be a great milestone for our company as well as for the fight against theCOVID-19 virus. We are pleased to be partnering with Primo Nutraceuticals and their team”

Richard Cindric, CEO of Primo Comments:

We are looking forward to working with Neo-Nosticsto provide a premium quality product. We anticipate the relationship to grow and look forward to updating our shareholders with our future milestones.” It is important to note that receiving the MDEL license from Health Canada has opened up a plethora of opportunities like this one which will result in revenue in the immediate short term for Primo and its shareholders.”

About Neo-Nostics(Suzhou) Bioengineering Co. Ltd.

Neo-Nostics ™ (Suzhou) Bioengineering Co., Ltd. which was established in 2015, is a professional company specialized in researching, developing, manufacturing, and distributing advanced medical instruments and in-vitro medical diagnostic products. Their products are usually used for fertility tests, infectious diseases tests, drugs of abuse tests, alcohol saliva tests, urinalysis reagent strips, cardiac marker tests, tumor marker tests, food and safety tests and animal disease tests.

To learn more about Neo-Nosticsplease visit: http://www.neo-nostics.com/en/

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the company; specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal
President and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals $PRMO.ca Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of #Psilocybin Mushrooms $AION.ca $PLNT.ca $SHRM.ca $CMPS

Posted by AGORACOM-JC at 11:32 AM on Wednesday, October 14th, 2020
  • Entered into a non-binding letter of intent with MedCan Biotechnologies Inc.
  • MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms

VANCOUVER, British Columbia, Oct. 14, 2020  — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“PRIMO” or the “Company”)

Primo Nutraceuticals Inc. has entered into a non-binding letter of intent (the “LOI”) with MedCan Biotechnologies Inc. (“MEDCAN BIOTECH”). MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms (commonly known as Magic Mushrooms).

Terms of Engagement

Health Canada (HC) has recently shifted towards psychedelic-assisted psychotherapies in safe, controlled environments as acceptable treatment options.

Pursuant to Section 56 exemption from the Canadian Drugs and Substances Act to treat anxiety associated diagnoses,MEDCAN BIOTECH will apply to Health Canada to receive approval under the Controlled Drug and Substances Act to allow MEDCAN BIOTECH to conduct research in order to effectively standardize the extraction of psilocybin from mushrooms.

The Health Canada permit by MEDCAN BIOTECH will allow to develop and license intellectual property (IP) exclusively for further product development by PRIMO via chemo-typing and geno-typing of 5 different mushrooms to understand their properties.

MEDCAN BIOTECHwill proceed to patent methods of analysis and results on behalf of PRIMO, whereby data generated will be used in the production of nutraceutical products.

All IPa nd products developed as a result of the analysis will become the property of PRIMO for their exclusive use.

Psychedelic research focused on psychedelic medicine and psychedelic drugs have demonstrated that these substances have potential for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder.The data produced can be used to generate premium natural health mushroom nutraceutical products. Genotyping can be used for the identification and labeling of different varieties of psilocybin mushrooms.

About MEDCAN BIOTECH

MEDCAN BIOTECH is an all-natural solution research and development company to better personal wellbeing.MEDCAN BIOTECH has already researched and formulated a range of cannabinoid products that combine with the multi-faceted cannabinoid component with other natural active ingredients to create products for Sleep, Mood, Mind and Pleasure presented online at: www.medcanbiotech.com

Founder, Dr. David Noshad is a part-time faculty member at British Columbia’s Thompson Rivers University as well as President of Bio-Act Technology which specializes in research and development consulting with respects to life-science, cannabis and agri-food industry.

In 2010, Dr. Noshad served as Principle Co-Investigator with the UBC’s Faculty of Pharmaceutical Sciences in cannabis pharmacology; characterizing cannabinoids and terpenes in cannabis and Humulus. The projects included in vitro culture techniques, biochemical analysis, molecular biology and genomic techniques.

About the Psychedelic Market

In the first half of 2020, US$150 million was raised by psychedelics-focused companies. The research group projects that the global psychedelics industry may reach a total value of US$7 billion by the year 2027. According to: https://reportonpsychedelics.com/

Richard Cindric, CEO of Primo Comments:

“It is an honor to have Dr. Noshad collaborating with us. We are confident his qualifications and experience in characterizing cannabinoids and terpenes in cannabis will translate into the development of IP focusing on psilocybin treatments for neuropsychiatric diseases.

By investing resources in functional mushroom beverages with Brujera Elixer, as well as developing an IP on psychedelics with MedCan, we will be able to introduce premium natural health mushroom products toboth thepsychedelic and non-psychedelic market places.”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License(MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

AndyJagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals Inc. $PRMO.ca Signs Letter of Intent with Brujera Elixirs Inc. to Formulate 4 Innovative Adaptogenic Mushroom-Infused Beverage Products

Posted by AGORACOM-JC at 9:41 AM on Thursday, October 1st, 2020
  • Company has decided to continue down that path by announcing that it has entered into a non-binding letter of intent (the “LOI”) with Brujera Elixirs Inc. (“Brujera”) to formulate an exclusive line of 4 “Innovative adaptogenic mushroom-infused” beverage products for the natural health and wellness market.
  • Product development and steps for final formulation will commence immediately upon signing of the definitive agreement with Brujera; which is expected to occur on or before October 30, 2020

VANCOUVER, British Columbia, Oct. 01, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo Nutra” or the “Company”) Further to the Company’s news release dated May 22, 2020 announcing that Primo Nutra received its Natural Product Number (“NPN) from Health Canada, the Company has decided to continue down that path by announcing that it has entered into a non-binding letter of intent (the “LOI”) with Brujera Elixirs Inc. (“Brujera”) to formulate an exclusive line of 4 “Innovative adaptogenic mushroom-infused” beverage products for the natural health and wellness market.

Product development and steps for final formulation will commence immediately upon signing of the definitive agreement with Brujera; which is expected to occur on or before October 30, 2020.

The specific types of functional mushrooms which will be used in formulating Primo Nutra’s exclusive beverages will be: Reishi , Cordyceps, Lion’s Mane and Chaga.

The Company was granted its first NPN ( 80099466) on May 22, 2020 for their lemon hand sanitizer. Primo Nutra will be focused on introducing 8 different natural health products to Canada’s health and wellness market.

About Brujera Elixirs Inc.

Launched by award winning B.C. master mixologist, sommelier and entrepreneur Kelly Ann Woods, Brujera is a house of brands which currently includes Boozewitch (sober-curious mixers) and State B Cannabis Beverage Co.Ms. Woods is an entrepreneur who has founded multiple companies in the CBD, cannabis, alcohol and non-alcohol beverage industry. In the last year, Kelly was named the 2019 RBC Canadian Woman Entrepreneur of the Year Award for Micro -Business Award ( https://www.youtube.com/watch?v=oLi9JSnhJ64 ). Woman of the Year from BC Business in addition to a CANIE Woman Entrepreneur award.

Nicknamed the “Boozewitch,” Quebec-born Kelly attended CEGEP in Montreal with a focus on theatre and worked as a flight attendant for Air Canada before moving to the West Coast. She spent years honing her drinks skills as a sommelier and doing hospitality work, all the while experimenting with beverage formulation. She is actively bringing a cannabis beverage to the US and Canadian markets under the name State B and opening an oceanfront wine bar in Squamish with a team of accomplished women in hospitality.

TERMS OF THE TRANSACTION

The LOI was signed on July 14, 2020. Pursuant to the LOI Primo Nutra and Brujera will seek to enter into a Definitive Consulting Agreement whereby Primo Nutra will create white label mushroom infused drinks for distribution in Canada and international markets while Brujera will create unique exclusive formulations for Primo Nutra’s mushroom-infused energy shot drinks.

Richard Cindric, CEO of Primo Comments:

“Ms. Woods experience in formulating functional CBD, cannabis, and alcoholic beverages is what we are looking for in a white-label partner. We are confident she is the right partner to introduce a mushroom based energy drink to compete with brands like Boost and Ensure. We are in a better position now than a year ago to peruse a line of energy drinks, as it was important to get a NPN number from Health Canada first.”

Kelly Ann Woods, CEO of BRUJERA Comments:

“We are pleased to be aligning ourselves with Primo for this line of adaptogenic mushroom drinks. At a time when immunity and cognitive function are at the forefront of people’s minds, this product is sure to be one in many people’s daily regime.”

The Global Energy Drink Market

According to Allied Market Research, the global energy drinks market size was valued at USD$53B in 2018 and is expected to reach USD$86B by 2026. https://www.alliedmarketresearch.com/energy-drink-market

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its NPN and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals $PRMO.ca and Dan Duquette, Former MLB Executive, Sign Definitive Agreement to Capitalize on Primo Receiving an MDEL License from Health Canada and announces Stock Option Grant

Posted by AGORACOM-JC at 9:09 AM on Thursday, September 24th, 2020
  • Further to the Letter of Intent with Duquette Consulting LLC referred to in the Company’s news release dated September 1, 2020 the Company has signed a Sales & Marketing Agreement to consummate the transaction
  • Primo expanded into the Canadian Medical Devices and personal protective equipment (“PPE”) markets, the Company pursued and was granted a Medical Device Establishment License
  • Primo and Duquette Consulting will work towards securing contracts and purchase orders for PPE equipment that includes N95 surgical masks, KN95 masks and surgical masks

VANCOUVER, British Columbia, Sept. 24, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that further to the Letter of Intent (the “LOI”) with Duquette Consulting LLC (“Duquette Consulting“) referred to in the Company’s news release dated September 1, 2020 the Company has signed a Sales & Marketing Agreement to consummate the transaction.

As Primo expanded into the Canadian Medical Devices and personal protective equipment (“PPE”) markets, the Company pursued and was granted a Medical Device Establishment License ( MDEL ) . The Company must comply with the regulations of Health Canada relating to manufacturing, importing, distributing and selling medical devices in Canada in order to receive a MDEL. Primo has demonstrated to Health Canada that the Company has met the regulatory requirements mandated of a MDEL license holder.

Primo and Duquette Consulting will work towards securing contracts and purchase orders for PPE equipment that includes N95 surgical masks, KN95 masks and surgical masks. Primo intends to acquire any and all additional necessary licensing and will take any additional steps required to import and/or distribute all four classes of medical devices in Canada, which include nitrile gloves, face shields, surgical gowns, respirators and testing kits.

TERMS OF THE TRANSACTION

The Sales & Marketing Agreement was made effective as of the 9 th day of September 2020.

Primo, a reporting issuer on the CSE was required to obtain an MDEL license from Health Canada to authorize the parties to sell and distribute PPE products for government contract purposes and to commercialize any related opportunities. To consummate this relationship Primo Nutraceuticals Inc., obtained the following approvals;

  1. a Government Procurement number; 806756235PG0001
  2. an Interim COVID-19 site license number; COV0950 and
  3. a Medical Device Establishment License number; 14815 .

Primo will assist Duquette Consulting in bidding on government tenders in Canada.

P PE Distribution Market worth $28.9 Billion by 2025 in North America and E.U

The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.

About Dan Duquette & Duquette Consulting LLC

Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers.

Duquette Consulting entered the PPE market by sourcing and selling products and supplies at a government & state level to help in the fight against COVID-19, securing, shipping and recently delivering over 5 million masks to the State of Maryland.
https://www.businesswire.com/news/home/20200727005153/en/Duquette-Consulting—State-Maryland-PPE-Fulfillment

Stock Options Granted

In addition, the Company has granted a total of 2,300,000 incentive stock options to directors, officers, employees and consultants under the Company’s stock option plan, which was approved by the Company’s board of directors. The incentive stock options (the “Options”) are exercisable at $0.15 per share and will expire on September 25, 2021. Following this option grant the Company has 2,300,000 Options outstanding.

Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it has received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals Inc. $PRMO.ca receives Medical Device Establishment License (MDEL) from Health Canada

Posted by AGORACOM-JC at 8:35 AM on Wednesday, September 16th, 2020
  • Announced it has been issued a Medical Device Establishment License (“MDEL”) from Health Canada
  • MDEL is a license issued to companies for the activities of manufacturing, importing and distributing (selling) of all four classes of medical devices for human use in Canada
  • These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few

VANCOUVER, British Columbia, Sept. 16, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce it has been issued a Medical Device Establishment License (“MDEL”) from Health Canada.

The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing (selling) of all four classes of medical devices for human use in Canada.

These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.

The MDEL license is issued by Health Canada’s Regulatory Operations and Enforcement Branch (ROEB) based on an attestation that the establishment meets all of HC’s MDEL regulatory requirements.

During an inspection by Health Canada, MDEL license holders must demonstrate to Health Canada that they meet the regulatory requirements attested to, having in place related medical devices that they intend to import and/or distribute (sell) in Canada.

Richard Cindric, CEO of Primo comments:

“Obtaining a Medical Device Establishment License is a milestone and a key step towards accessing the MDEL market share through the sale of already Health Canada approved commercialized devices. We have seen an increase in demand for PPE and medical devices since the COVID-19 pandemic surfaced. Receiving the MDEL license allows for more efficient, convenient and cost effective delivery of PPE and medical devices to Canadians including institutional markets and those managed by Federal and Provincial governments.”

Joel DeBellefeuille, Director of Primo comments: 

“The team has been working feverishly over the last few weeks focusing solely on delivering important catalysts. This one is definitely a major game-changer!”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo”  & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it has received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected].

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.No regulatory authority has approved or disapproved the information contained in this news release.